Olenia

Bidens pilosa contains flavonoids (kaempferol at 32.87 mg/g, gallic acid at 33.3 mg/g), polyacetylenes, and sesquiterpene lactones that exert antimicrobial, anti-inflammatory, and antioxidant effects by scavenging free radicals and suppressing pro-inflammatory cytokines TNF, IL-6, IL-1β, and IL-8. In vitro studies demonstrate antioxidant activity with DPPH IC50 values of 80.45 µg/mL in leaf extracts and antimicrobial minimum inhibitory concentrations of 80 µg/mL against Escherichia coli, though no human clinical trials have yet confirmed these effects at therapeutic doses.

Origin & History

Bidens pilosa is a pantropical annual herb native to South America that has naturalized extensively across Africa, Asia, Australia, and the Pacific Islands, including Hawaii where it is known as Olenia. It thrives in disturbed soils, roadsides, agricultural margins, and humid lowland environments from sea level to approximately 3,000 meters elevation. Traditional cultivation is minimal, as the plant grows prolifically as a pioneer weed, with leaves and flowering tops harvested from wild populations for medicinal use.

Historical & Cultural Context

Bidens pilosa has a deep and geographically broad history of medicinal use spanning Hawaiian, Pacific Island, African, Asian, and South American traditional medicine systems, where it has been employed for wound care, infectious diseases, malaria, gastrointestinal disorders, and inflammatory conditions for centuries. In Hawaii, the plant is recognized as Olenia and occupies a role in traditional healing (lāʻau lapaʻau) particularly for its antimicrobial and vulnerary (wound-healing) properties, with fresh leaf poultices applied directly to infected skin lesions and cuts. Across sub-Saharan Africa and parts of Asia, the plant's leaves and roots are prepared as decoctions for fever, malaria, and respiratory infections, with distinct cultural preparations reflecting local pharmacopoeial knowledge. The plant's status as a widespread weedy colonizer has paradoxically facilitated its integration into diverse healing traditions across colonized and post-colonial Pacific and tropical regions, making it one of the most widely used medicinal weeds globally.

Health Benefits

- **Antimicrobial Activity**: Polyacetylenes and flavonoid fractions from leaf and flower extracts inhibit the growth of bacterial pathogens including E. coli at MIC values of 80 µg/mL, supporting the traditional Hawaiian and Pacific Islands use for infected wounds and topical infections.
- **Antioxidant Protection**: Leaf extracts rich in gallic acid (33.3 mg/g) and kaempferol (32.87 mg/g) scavenge DPPH radicals with IC50 values as low as 13.35 µg/mL in flower fractions, reducing oxidative cellular damage correlated with total phenolic and flavonoid content.
- **Anti-inflammatory Effects**: Bidens pilosa extracts lower circulating levels of TNF, IL-6, IL-1β, and IL-8 in preclinical models while simultaneously boosting glutathione and reducing malondialdehyde, a marker of lipid peroxidation, suggesting broad attenuation of the inflammatory cascade.
- **Wound Healing Support**: Traditional topical application of leaf poultices exploits the plant's combined antimicrobial and anti-inflammatory properties to reduce microbial burden at wound sites and limit inflammatory tissue damage, consistent with the ethnobotanical record across Hawaii and Pacific Island communities.
- **Anticancer Potential**: The presence of paclitaxel at approximately 15.0 mg/g and polyacetylene fractions contributes to cytotoxic activity against KB-3-1 cancer cells with an IC50 of 99.56 µg/mL in vitro, indicating potential antiproliferative mechanisms though human data are entirely absent.
- **Antimalaria Activity**: Sesquiterpene lactones and polyacetylenes identified in Bidens pilosa have demonstrated in vitro activity against Plasmodium species in regional ethnopharmacological studies, consistent with antimalarial uses recorded across sub-Saharan Africa and Pacific populations.
- **Hepatoprotective and Metabolic Effects**: Polyphenol-rich fractions, particularly rutin, hyperoside, and 4,5-O-dicaffeoylquinic acid, have shown preliminary hepatoprotective and glucose-regulatory activity in animal models, with evidence suggesting modulation of oxidative stress pathways in liver tissue.

How It Works

Flavonoids including kaempferol, rutin, and hyperoside donate hydrogen atoms to neutralize reactive oxygen species, with activity quantified at DPPH IC50 80.45 µg/mL and ABTS IC50 171.6 µg/mL, and this antioxidant capacity correlates directly with total flavonoid and phenolic content across plant fractions. Polyacetylenes and sesquiterpene lactones disrupt microbial membrane integrity and inhibit microbial enzyme systems, while also interfering with tumor cell proliferation through induction of apoptosis and inhibition of mitotic spindle formation, the latter mechanism shared with paclitaxel (taxol), which is quantified at 15.0 mg/g in leaf extracts. Anti-inflammatory action proceeds through suppression of nuclear factor-kappa B (NF-κB) signaling, reducing transcription of TNF, IL-6, IL-1β, and IL-8, and simultaneously upregulating endogenous antioxidant defenses by increasing glutathione levels and reducing malondialdehyde accumulation. Caffeic acid derivatives such as 4,5-O-dicaffeoylquinic acid additionally inhibit cyclooxygenase enzymes and modulate prostaglandin biosynthesis, contributing to the plant's multi-target anti-inflammatory profile.

Scientific Research

The evidence base for Bidens pilosa consists almost entirely of in vitro biochemical assays and animal model studies, with no published randomized controlled trials involving human participants identified in the current literature. Phytochemical characterization studies have rigorously quantified bioactive compounds using validated HPLC methods with analytical recovery rates of 94.87–105.19%, lending credibility to the compositional data, and a total of 301 compounds have been reported across the plant's phytochemical profile. Antimicrobial studies report MIC values of 80 µg/mL against E. coli and cytotoxicity against KB-3-1 cancer cells at IC50 99.56 µg/mL, while antioxidant assays yield IC50 values ranging from 13.35 µg/mL (flowers, DPPH) to 117.2 µg/mL (stems), demonstrating part-specific bioactivity gradients. Overall, the body of preclinical evidence is internally consistent and mechanistically plausible, but the complete absence of human clinical trials means that efficacy and safety in human populations cannot be established, placing Bidens pilosa firmly in the preliminary-to-moderate evidence category.

Clinical Summary

No human randomized controlled trials or controlled observational studies for Bidens pilosa (Olenia) have been identified in the current peer-reviewed literature, meaning all efficacy data derive exclusively from in vitro cell-based experiments and, to a lesser extent, animal models. Outcomes measured in preclinical settings include antioxidant IC50 values (DPPH 80.45 µg/mL, ABTS 171.6 µg/mL), antimicrobial MICs (80 µg/mL vs. E. coli), cytotoxicity against cancer cell lines (IC50 99.56 µg/mL, KB-3-1), and cytokine modulation (TNF, IL-6, IL-1β, IL-8 reduction). The confidence in translating these results to human therapeutic outcomes is low given the absence of pharmacokinetic data, bioavailability studies, and dose-response data in humans. Clinical investigation through phase I safety trials followed by proof-of-concept efficacy studies is needed before any therapeutic claims can be substantiated for Olenia in Pacific Islands or other populations.

Nutritional Profile

Bidens pilosa leaves are rich in polyphenolic phytochemicals including gallic acid (33.3 mg/g dry extract), kaempferol (32.87 mg/g), catechin (16.0 mg/g), and ferulic acid (0.58 mg/g), with total phenolic content quantified at 72 µg gallic acid equivalents per mg extract and total flavonoid content at 123.3 µg quercetin equivalents per mg extract. Notable minor constituents include rutin, hyperoside, 4,5-O-dicaffeoylquinic acid, and paclitaxel (15.0 mg/g in leaf extract), alongside polyacetylenes, sesquiterpene lactones, aurones, and chalcones contributing to a phytochemical inventory of over 301 identified compounds. Macronutrient and micronutrient composition of the whole leaf (vitamins, minerals, fiber) has not been comprehensively characterized in peer-reviewed analytical studies, limiting nutritional profiling beyond the phytochemical fraction. Bioavailability of key flavonoids such as kaempferol and catechin is expected to be influenced by food matrix interactions, gut microbiome-mediated transformation, and the extraction solvent used, though no human pharmacokinetic data for Bidens pilosa specifically have been published.

Preparation & Dosage

- **Traditional Leaf Poultice**: Fresh leaves crushed and applied topically to wounds, skin infections, and inflamed tissue; no standardized weight-to-area dosing established in the ethnobotanical record.
- **Hydroethanolic Infusion/Maceration**: Dried leaves steeped in water-ethanol mixtures (typically 50–70% ethanol); used empirically in traditional practice but no validated human dose range established.
- **Methanol or Acetonitrile Extract (Research Grade)**: Prepared at 1 mg/mL concentrations for in vitro and analytical studies; not applicable to supplemental use.
- **Supercritical Fluid Extract**: Used in advanced phytochemical extraction to concentrate polyacetylene and flavonoid fractions; no commercial supplement form currently standardized.
- **Standardization**: No pharmacopoeial standardization exists; research preparations are characterized by TPC (72 µg GAE/mg extract) and TFC (123.3 µg quercetin equivalents/mg extract) as quality markers.
- **Dosage Note**: No safe or effective human dose has been established through clinical trials; all dosing in current use is empirical and based on traditional practice, and use should be approached cautiously pending human safety data.

Synergy & Pairings

Bidens pilosa's flavonoid-rich profile, particularly kaempferol and catechin, may exhibit additive or synergistic antioxidant and anti-inflammatory effects when combined with other polyphenol-containing botanicals such as green tea extract (EGCG) or turmeric (curcumin), as convergent NF-κB suppression and free radical scavenging have been demonstrated for these compound classes individually. The antimicrobial polyacetylene fraction may complement standardized propolis extracts or honey-based wound formulations in topical applications, leveraging distinct mechanisms of membrane disruption versus biofilm inhibition to broaden antimicrobial spectrum. No formal synergy or combination studies involving Bidens pilosa with other named supplement ingredients have been published, and these pairings remain speculative pending in vitro or in vivo co-administration research.

Safety & Interactions

Human safety data for Bidens pilosa (Olenia) are essentially absent from the peer-reviewed clinical literature, and no maximum tolerated dose, no-observed-adverse-effect level, or standardized therapeutic dose has been established through formal toxicological or clinical studies in humans. In vitro cytotoxicity at IC50 99.56 µg/mL against cancer cell lines indicates that concentrated extracts possess bioactive potency that warrants caution at high doses, but whether this translates to systemic toxicity in vivo at traditional-use concentrations is unknown. No specific drug interactions have been formally documented, though the presence of paclitaxel-related compounds and potent flavonoids suggests theoretical interactions with anticoagulants (e.g., warfarin), cytochrome P450-metabolized drugs, and immunosuppressive agents should be considered. Use during pregnancy and lactation is not supported by any safety evidence and should be avoided; individuals with known plant-based allergies, particularly to the Asteraceae (Compositae) family, should exercise caution given the significant risk of cross-reactive hypersensitivity.